150 related articles for article (PubMed ID: 27267853)
1. Recurrent Mutations in the MTOR Regulator RRAGC in Follicular Lymphoma.
Ying ZX; Jin M; Peterson LF; Bernard D; Saiya-Cork K; Yildiz M; Wang S; Kaminski MS; Chang AE; Klionsky DJ; Malek SN
Clin Cancer Res; 2016 Nov; 22(21):5383-5393. PubMed ID: 27267853
[TBL] [Abstract][Full Text] [Related]
2. Raptor mediates the selective inhibitory effect of cardamonin on RRAGC-mutant B cell lymphoma.
Liu Y; Zhu Y; Chen H; Zhou J; Niu P; Shi D
BMC Complement Med Ther; 2023 Sep; 23(1):336. PubMed ID: 37749558
[TBL] [Abstract][Full Text] [Related]
3. Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma.
Okosun J; Wolfson RL; Wang J; Araf S; Wilkins L; Castellano BM; Escudero-Ibarz L; Al Seraihi AF; Richter J; Bernhart SH; Efeyan A; Iqbal S; Matthews J; Clear A; Guerra-Assunção JA; Bödör C; Quentmeier H; Mansbridge C; Johnson P; Davies A; Strefford JC; Packham G; Barrans S; Jack A; Du MQ; Calaminici M; Lister TA; Auer R; Montoto S; Gribben JG; Siebert R; Chelala C; Zoncu R; Sabatini DM; Fitzgibbon J
Nat Genet; 2016 Feb; 48(2):183-8. PubMed ID: 26691987
[TBL] [Abstract][Full Text] [Related]
4. Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.
Ghosh AP; Marshall CB; Coric T; Shim EH; Kirkman R; Ballestas ME; Ikura M; Bjornsti MA; Sudarshan S
Oncotarget; 2015 Jul; 6(20):17895-910. PubMed ID: 26255626
[TBL] [Abstract][Full Text] [Related]
5. De novo missense variants in RRAGC lead to a fatal mTORopathy of early childhood.
Reijnders MRF; Seibt A; Brugger M; Lamers IJC; Ott T; Klaas O; Horváth J; Rose AMS; Craghill IM; Brunet T; Graf E; Mayerhanser K; Hellebrekers D; Pauck D; Neuen-Jacob E; Rodenburg RJT; Wieczorek D; Klee D; Mayatepek E; Driessen G; Bindermann R; Averdunk L; Lohmeier K; Sinnema M; Stegmann APA; Roepman R; Poulter JA; Distelmaier F
Genet Med; 2023 Jul; 25(7):100838. PubMed ID: 37057673
[TBL] [Abstract][Full Text] [Related]
6. Follicular lymphoma-associated mutations in vacuolar ATPase ATP6V1B2 activate autophagic flux and mTOR.
Wang F; Gatica D; Ying ZX; Peterson LF; Kim P; Bernard D; Saiya-Cork K; Wang S; Kaminski MS; Chang AE; Phillips T; Klionsky DJ; Malek SN
J Clin Invest; 2019 Mar; 129(4):1626-1640. PubMed ID: 30720463
[TBL] [Abstract][Full Text] [Related]
7. Oncogenic Rag GTPase signaling enhances B cell activation and drives follicular lymphoma sensitive to pharmacological inhibition of mTOR.
Ortega-Molina A; Deleyto-Seldas N; Carreras J; Sanz A; Lebrero-Fernández C; Menéndez C; Vandenberg A; Fernández-Ruiz B; Marín-Arraiza L; de la Calle Arregui C; Belén Plata-Gómez A; Caleiras E; de Martino A; Martínez-Martín N; Troulé K; Piñeiro-Yáñez E; Nakamura N; Araf S; Victora GD; Okosun J; Fitzgibbon J; Efeyan A
Nat Metab; 2019 Aug; 1(8):775-789. PubMed ID: 31579886
[TBL] [Abstract][Full Text] [Related]
8. Activating STAT6 mutations in follicular lymphoma.
Yildiz M; Li H; Bernard D; Amin NA; Ouillette P; Jones S; Saiya-Cork K; Parkin B; Jacobi K; Shedden K; Wang S; Chang AE; Kaminski MS; Malek SN
Blood; 2015 Jan; 125(4):668-79. PubMed ID: 25428220
[TBL] [Abstract][Full Text] [Related]
9. Rheb binds and regulates the mTOR kinase.
Long X; Lin Y; Ortiz-Vega S; Yonezawa K; Avruch J
Curr Biol; 2005 Apr; 15(8):702-13. PubMed ID: 15854902
[TBL] [Abstract][Full Text] [Related]
10. Follicular Lymphoma-associated BTK Mutations are Inactivating Resulting in Augmented AKT Activation.
Hu N; Wang F; Sun T; Xu Z; Zhang J; Bernard D; Xu S; Wang S; Kaminski M; Devata S; Phillips T; Malek SN
Clin Cancer Res; 2021 Apr; 27(8):2301-2313. PubMed ID: 33419778
[TBL] [Abstract][Full Text] [Related]
11. De novo RRAGC mutation activates mTORC1 signaling in syndromic fetal dilated cardiomyopathy.
Long PA; Zimmermann MT; Kim M; Evans JM; Xu X; Olson TM
Hum Genet; 2016 Aug; 135(8):909-917. PubMed ID: 27234373
[TBL] [Abstract][Full Text] [Related]
12. Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma.
Okosun J; Bödör C; Wang J; Araf S; Yang CY; Pan C; Boller S; Cittaro D; Bozek M; Iqbal S; Matthews J; Wrench D; Marzec J; Tawana K; Popov N; O'Riain C; O'Shea D; Carlotti E; Davies A; Lawrie CH; Matolcsy A; Calaminici M; Norton A; Byers RJ; Mein C; Stupka E; Lister TA; Lenz G; Montoto S; Gribben JG; Fan Y; Grosschedl R; Chelala C; Fitzgibbon J
Nat Genet; 2014 Feb; 46(2):176-181. PubMed ID: 24362818
[TBL] [Abstract][Full Text] [Related]
13. Amino acid-dependent NPRL2 interaction with Raptor determines mTOR Complex 1 activation.
Kwak SS; Kang KH; Kim S; Lee S; Lee JH; Kim JW; Byun B; Meadows GG; Joe CO
Cell Signal; 2016 Feb; 28(2):32-41. PubMed ID: 26582740
[TBL] [Abstract][Full Text] [Related]
14. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ
Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631
[TBL] [Abstract][Full Text] [Related]
15. Mutations in linker histone genes HIST1H1 B, C, D, and E; OCT2 (POU2F2); IRF8; and ARID1A underlying the pathogenesis of follicular lymphoma.
Li H; Kaminski MS; Li Y; Yildiz M; Ouillette P; Jones S; Fox H; Jacobi K; Saiya-Cork K; Bixby D; Lebovic D; Roulston D; Shedden K; Sabel M; Marentette L; Cimmino V; Chang AE; Malek SN
Blood; 2014 Mar; 123(10):1487-98. PubMed ID: 24435047
[TBL] [Abstract][Full Text] [Related]
16. Rheb, an activator of target of rapamycin, in the blackback land crab, Gecarcinus lateralis: cloning and effects of molting and unweighting on expression in skeletal muscle.
MacLea KS; Abuhagr AM; Pitts NL; Covi JA; Bader BD; Chang ES; Mykles DL
J Exp Biol; 2012 Feb; 215(Pt 4):590-604. PubMed ID: 22279066
[TBL] [Abstract][Full Text] [Related]
17. Regulation of folliculin (the BHD gene product) phosphorylation by Tsc2-mTOR pathway.
Piao X; Kobayashi T; Wang L; Shiono M; Takagi Y; Sun G; Abe M; Hagiwara Y; Zhang D; Okimoto K; Kouchi M; Matsumoto I; Hino O
Biochem Biophys Res Commun; 2009 Nov; 389(1):16-21. PubMed ID: 19695222
[TBL] [Abstract][Full Text] [Related]
18. Somatic Mutations in the MTOR gene cause focal cortical dysplasia type IIb.
Nakashima M; Saitsu H; Takei N; Tohyama J; Kato M; Kitaura H; Shiina M; Shirozu H; Masuda H; Watanabe K; Ohba C; Tsurusaki Y; Miyake N; Zheng Y; Sato T; Takebayashi H; Ogata K; Kameyama S; Kakita A; Matsumoto N
Ann Neurol; 2015 Sep; 78(3):375-86. PubMed ID: 26018084
[TBL] [Abstract][Full Text] [Related]
19. Tumor suppressor gene methylation in follicular lymphoma: a comprehensive review.
Hayslip J; Montero A
Mol Cancer; 2006 Oct; 5():44. PubMed ID: 17026765
[TBL] [Abstract][Full Text] [Related]
20. Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors.
Kong Y; Si L; Li Y; Wu X; Xu X; Dai J; Tang H; Ma M; Chi Z; Sheng X; Cui C; Guo J
Clin Cancer Res; 2016 Feb; 22(4):1018-27. PubMed ID: 26490311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
